An observational study in Chordoma, sponsored by National Cancer Institute (NCI). Recruiting at 1 site in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by National Cancer Institute (NCI) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Chordoma with a site in United States — 6 open to participants now, 16 under way, none of them phase 3. Chordoma · United States.
Among the 44 studies in Chordoma with a site in United States, this one is the 3rd largest by planned enrollment of the 11 observational ones that give a count, is one of 4 that started in 2019, is one of 11 observational ones, reaches primary completion later than 11 of the 14 other live ones, and was the 28th registered.
68 studies on the registry are indexed under Chordoma; 15 are open to participants now.
Browse Chordoma studies →6 of the 44 studies in Chordoma with a site in United States are open now. Recruiting first, the newest first:
University of Florida · Sites in United States
Ages 6 mo–25 yrs
Saint John's Cancer Institute · Sites in United States
Ages 18+
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 15+
National Cancer Institute (NCI) · Sites in United States
Ages 1–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Chordoma studies recruiting now, 9 (75%) set no upper age limit and 1 (8%) stops at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 17
First in 1998; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 71 across 16 observational studies indexed under Chordoma.
Median enrollment 29 across the 32 interventional studies, 150 across the 11 observational. Of the 25 that completed or were terminated, 8 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 44 have an industry lead sponsor. The 10 most frequent:
National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 335 are open to participants now.
Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.
National Cancer Institute (NCI) has 7 studies filed under Chordoma — fewer than ten, so there is no comparison to draw.
6 of the studies in Chordoma with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06794645Saint John's Cancer InstitutePembrolizumab and Pemetrexed for Progressive Chordoma | 2026-11-30 |
| NCT04087902Ohio State UniversityLong-Term Longitudinal QoL in Patients Undergoing EEA | 2026-12-31 |
| NCT05407441Susan Chi, MDTazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors | 2027-02-01 |
| NCT06957327Memorial Sloan Kettering Cancer CenterA Study of ERAS-601 in People With Chordoma | 2027-04 |
| NCT01346124Massachusetts General HospitalHigh Dose Intensity Modulated Proton Radiation Treatment +/- Surgical Resection of Sarcomas of the Spine, Sacrum and Base of Skull | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 44 studies in Chordoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background:
Chordoma is a rare type of bone cancer. It occurs in the skull base or spine. Researchers want to study people with chordoma in different ways. They hope this will help them design better future treatments and supportive care studies for this disease.
Objective:
To learn more about chordoma by looking at its clinical course, how it appears on imagine scans, and how it responds to therapies and treatments.
Eligibility:
People ages 2 and older with chordoma who are enrolled in NCI protocol 19-C-0016
Design:
Participants will be screened with their medical history.
Participants will have a visit to examine their disease. This will include:
Participants will have other tests every 6-12 months:
Participants or their home doctors will be contacted every 6 12 months. They will be asked to provide information about their disease. This could include test results and imaging evaluations.
Some participants may be asked to come to the clinic for more visits.
Background:
Objective:
-To characterize the natural history of chordoma, including clinical presentation and patterns of disease progression.
Eligibility:
Design:
The criteria were revised on the registry on Oct 1, 2026. See what changed
primary clinical
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
EXCLUSION CRITERIA:
-None
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with confirmed chordoma.
To characterize the natural history of chordoma, including clinical presentation and patterns of disease progression
Natural history of chordoma, including clinical presentation and patterns of disease progression
Time frame: 10 years
Plan to share: Yes — All IPD recorded in the medical record will be shared with intramural investigators upon request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Clinical data available during the study and indefinitely.
Access criteria: Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.
Started Apr 2019 (actual). Primary completion is estimated for Dec 2029, 128 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Cancer Institute (NCI) →